ASH 2019 | Mutational profiling reveals subset of R/R AML that may benefit from quizartinib
Mark Levis
• 7 Dec 2019
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, explains the effect of co-mutations and FLT3-ITD variant allele frequency on response to quizartinib or salvage chemotherapy in relapsed/refractory acute myeloid leukemia (R/R AML), using data from the QuANTUM-R trial (NCT02039726). In particular, the results of the anslysis performed indicated that a specific subset of R/R AML patients may benefit from quizartinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
